Search all trials

Find therapies in clinical trials near you – page 6

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Breast cancer metastatic+2

Not recruiting

Registered drug

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Pertuzumab

Contact Research Centre

Breast cancer metastatic+1

Not recruiting

Registered drugNo placebo

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan

Contact Research Centre

Breast cancer metastatic+3

Not recruiting

Registered drugNo placebo

Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Everolimus

Contact Research Centre

Breast cancer metastatic+2

Not recruiting

Registered drugNo placebo

Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years
Substances:Carboplatin

Contact Research Centre

Breast cancer metastatic+1

Not recruiting

Registered drugNo placebo

Study of PF-07220060 and PF-07104091 with Endocrine Therapy for Patients with Advanced HR-positive HER2-negative Breast Cancer

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Fulvestrant

Contact Research Centre

Breast cancer metastatic+4

Not recruiting

Registered drugNo placebo

Study on PF-07220060, Letrozole, and Fulvestrant for Patients with Advanced Breast Cancer, Prostate Cancer, and Other Solid Tumors

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Fulvestrant

Contact Research Centre

Breast cancer metastatic

Not recruiting

Registered drugNo placebo

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Fulvestrant

Contact Research Centre

Breast cancer metastatic+2

Not recruiting

Registered drugNo placebo

Study on Detecting Untreated Brain Metastases in Lung, Breast, and Melanoma Cancer Patients Using Fluorodopa (18F)

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fluorodopa (18F)

Contact Research Centre

Breast cancer metastatic+1

Not recruiting

Registered drugNo placebo

Study of Fulvestrant and Samuraciclib for Patients with Advanced HR Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

Hungary

Participants:18–64 years
Substances:Fulvestrant

Contact Research Centre

Breast cancer metastatic+2

Not recruiting

InvestigationalNo placebo

Study of Patritumab Deruxtecan for Patients with Brain Metastases from Advanced Breast or Lung Cancer and Leptomeningeal Disease from Solid Tumors

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Patritumab Deruxtecan

Contact Research Centre

Breast cancer metastatic

Not recruiting

Registered drugNo placebo

Study of Elacestrant for Patients with Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer Who Have Not Used CDK4/6 Inhibitors

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Elacestrant

Contact Research Centre

Breast cancer metastatic+1

Not recruiting

Registered drugNo placebo

Study on Imaging with 89Zr-Atezolizumab to Monitor Immune Responses in Patients with Metastatic Triple Negative Breast Cancer Using Atezolizumab and Drug Combination

Registered drugNo placebo

Sweden

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Find therapies in clinical trials near you – page 6

84 trials match your criteria

Breast cancer metastatic+2

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Breast cancer metastatic+1

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

Breast cancer metastatic+3

Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Breast cancer metastatic+2

Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Breast cancer metastatic+1

Study of PF-07220060 and PF-07104091 with Endocrine Therapy for Patients with Advanced HR-positive HER2-negative Breast Cancer

Breast cancer metastatic+4

Study on PF-07220060, Letrozole, and Fulvestrant for Patients with Advanced Breast Cancer, Prostate Cancer, and Other Solid Tumors

Breast cancer metastatic

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Breast cancer metastatic+2

Study on Detecting Untreated Brain Metastases in Lung, Breast, and Melanoma Cancer Patients Using Fluorodopa (18F)

Breast cancer metastatic+1

Study of Fulvestrant and Samuraciclib for Patients with Advanced HR Positive, HER2-Negative Breast Cancer

Breast cancer metastatic+2

Study of Patritumab Deruxtecan for Patients with Brain Metastases from Advanced Breast or Lung Cancer and Leptomeningeal Disease from Solid Tumors

Breast cancer metastatic

Study of Elacestrant for Patients with Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer Who Have Not Used CDK4/6 Inhibitors

Breast cancer metastatic+1

Study on Imaging with 89Zr-Atezolizumab to Monitor Immune Responses in Patients with Metastatic Triple Negative Breast Cancer Using Atezolizumab and Drug Combination

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.